TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23262808

Group type: EXPERIMENTAL
Intervention: Massage intervention (multimedia instructional program including a 78-min DVD and 66-page manual)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Attention control (reading to patients)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Massage intervention (multimedia instructional program)
Number of subjects: 97
Study: 21460356

Group type: EXPERIMENTAL
Intervention: Oxabact (oral administration)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 18087163

Group type: EXPERIMENTAL
Intervention: Omalizumab at a dose of >=0.016 mg/kg/IgE every 4 weeks
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 17
Study: 16291387

Group type: EXPERIMENTAL
Intervention: PCEA (ropivacaine 3.2 mg + fentanyl 8 microg/dose)
Number of subjects: 70

Group type: COMPARATOR
Intervention: IV-PCA (morphine 2 mg/dose)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: PCEA
Number of subjects: 70

Group type: COMPARATOR
Intervention: IV-PCA
Number of subjects: 70
Study: 12002503

Group type: COMPARATOR
Intervention: Manipulation (MUA) and application of an above-elbow cast alone
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Percutaneous Kirschner (K-) wire insertion in addition to manipulation and casting
Number of subjects: 68
Study: 10460982

Group type: EXPERIMENTAL
Intervention: 14‐day training of a relaxation therapy including a 30‐minute lullaby‐like, rhythmically dominated music with gradually decreasing tempi
Number of subjects: 28

Group type: COMPARATOR
Intervention: No training in the control group
Number of subjects: 28
Study: 8529732

Group type: EXPERIMENTAL
Intervention: Oral diclofenac 50 mg 3 times a day for 7 days
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 1695232

Group type: EXPERIMENTAL
Intervention: Continuous challenge with pollen antigens for 6 hours
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Interrupted challenge with pollen antigens (Ag) for 1 hour, buffer for 4 hours, then Ag during the sixth hour
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Continuous challenge with codeine (C) for up to 5 hours
Number of subjects: 11
Study: 619075

Group type: EXPERIMENTAL
Intervention: Cendehill vaccine
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: HPV‐77 vaccine
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: RA‐27/3 vaccine (subcutaneously)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: RA‐27/3 vaccine (intranasally)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: RA‐27/3 vaccine
Number of subjects: 113
Study: 30917806

Group type: EXPERIMENTAL
Intervention: Loaded self-managed exercise programme
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual physiotherapy
Number of subjects: 60
Study: 28749550

Group type: EXPERIMENTAL
Intervention: Moderate-to-high intensity combined resistance-endurance training for 6 months, 2 days per week
Number of subjects: 54

Group type: COMPARATOR
Intervention: Usual care recommendations (Control Group)
Number of subjects: 54
Study: 25832859

Group type: EXPERIMENTAL
Intervention: TCZ IV/SC
Number of subjects: 319

Group type: COMPARATOR
Intervention: TCZ SC/SC
Number of subjects: 319
Study: 23928094

Group type: EXPERIMENTAL
Intervention: BIIB023 (0.03-20 mg/kg)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 21318017

Group type: EXPERIMENTAL
Intervention: Handwashing with water
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Handwashing with non‐antibacterial soap and water
Number of subjects: 20

Group type: COMPARATOR
Intervention: No handwashing
Number of subjects: 20
Study: 19861525

Group type: EXPERIMENTAL
Intervention: Urinary PGE-M levels in gastric cancer cases
Number of subjects: 153

Group type: COMPARATOR
Intervention: Urinary PGE-M levels in controls
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Quartiles of urinary PGE-M levels
Number of subjects: 153
Study: 17545850

Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 1059

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1059
Study: 15318307

Group type: EXPERIMENTAL
Intervention: Indwelling dialysate in the peritoneal cavity
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: No indwelling dialysate in the peritoneal cavity
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 20
Study: 11573658

Group type: EXPERIMENTAL
Intervention: Propofol infusion at 2 microg ml(‐1) with two word lists (category examples and nonsense words)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Propofol infusion at 5 microg ml(‐1) with nonsense words before tracheal intubation and category examples during intubation
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Propofol infusion at 5 microg ml(‐1) with category examples before and nonsense words during intubation
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (12 patients) completed the category generation test without receiving category examples during anaesthesia
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Category generation task during intubation
Number of subjects: 36
Study: 9591926

Group type: EXPERIMENTAL
Intervention: 8 microg of a 2.8‐microm monodisperse ipratropium bromide aerosol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 40 microg from a metered‐dose inhaler plus spacer
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo aerosol
Number of subjects: 10
Study: 7846921

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg b.i.d. with preoperative cathartic (group OA, n = 159)
Number of subjects: 327

Group type: COMPARATOR
Intervention: No oral antibiotic (group NOA, n = 168)
Number of subjects: 327
Study: 3406688

Group type: EXPERIMENTAL
Intervention: Cryoanalgesia applied intraoperatively to the intercostal nerves
Number of subjects: 144

Group type: COMPARATOR
Intervention: Bupivacaine‐adrenaline intercostal blockade
Number of subjects: 144
Study: 30563365

Group type: EXPERIMENTAL
Intervention: Short form intervention
Number of subjects: 112

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 112
Study: 29748350

Group type: EXPERIMENTAL
Intervention: Worsening renal function (WRF) defined as a creatinine increase of ≥0.3 mg/dL
Number of subjects: 2033

Group type: EXPERIMENTAL
Intervention: Worsening renal function (WRF)
Number of subjects: 2033
Study: 28376921

Group type: EXPERIMENTAL
Intervention: Value-based emotion-focused educational programme (4 sessions + 1 booster over 4 months)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Attention-control group (3 meetings over 4 months)
Number of subjects: 198
Study: 26308169

Group type: EXPERIMENTAL
Intervention: Oratane
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Australian-sourced Roaccutane
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mexican-sourced Roaccutan
Number of subjects: 0
Study: 23207892

Group type: EXPERIMENTAL
Intervention: Cluster set (CS) with 30-second rest intervals
Number of subjects: 12

Group type: COMPARATOR
Intervention: 5RM until failure
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cluster set (CS)
Number of subjects: 12
Study: 20924294

Group type: EXPERIMENTAL
Intervention: Continuous epidural infusion morphine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Continuous epidural infusion morphine with Bupivacaine
Number of subjects: 120

Group type: COMPARATOR
Intervention: Intravenous morphine
Number of subjects: 120
Study: 18420875

Group type: EXPERIMENTAL
Intervention: Combined ultrasound and neurostimulation guidance (US-NS group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Neurostimulation alone (NS group)
Number of subjects: 60
Study: 15385274

Group type: EXPERIMENTAL
Intervention: Multidisciplinary case conferences
Number of subjects: 154

Group type: COMPARATOR
Intervention: Control group (no case conferences)
Number of subjects: 154
Study: 11733916

Group type: EXPERIMENTAL
Intervention: Stent (group I)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Bladder catheterization (group II)
Number of subjects: 44
Study: 9620818

Group type: EXPERIMENTAL
Intervention: Intervention group (mothers taught comforting and interacting techniques within 24 hours of delivery)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Maternal scores in the intervention group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (mothers not receiving the intervention)
Number of subjects: 60
Study: 7802475

Group type: EXPERIMENTAL
Intervention: Suprapubic techniques (Marshall‐Marchetti‐Krantz and Burch)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Vaginal techniques (Raz I and II)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Burch colposuspension technique
Number of subjects: 31
Study: 3162870

Group type: EXPERIMENTAL
Intervention: Tiaprofenic acid
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 10
Study: 31571329

Group type: EXPERIMENTAL
Intervention: Botulinum Toxin A (BTX‐A) infiltration
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (saline) infiltration
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Physical therapy (PT) programme (12 sessions)
Number of subjects: 50
Study: 28631250

Group type: EXPERIMENTAL
Intervention: SRP + probiotic (Lactobacillus salivarius NK02)
Number of subjects: 2

Group type: COMPARATOR
Intervention: SRP + placebo
Number of subjects: 2
Study: 26837632

Group type: EXPERIMENTAL
Intervention: Integrated FP/HIV services (N = 12)
Number of subjects: 960

Group type: COMPARATOR
Intervention: Standard referral for FP (N = 6)
Number of subjects: 960
Study: 25255021

Group type: EXPERIMENTAL
Intervention: Truview EVO2 laryngoscope with CPR
Number of subjects: 30

Group type: COMPARATOR
Intervention: Macintosh laryngoscope with CPR
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Truview EVO2 laryngoscope without CPR
Number of subjects: 30

Group type: COMPARATOR
Intervention: Macintosh laryngoscope without CPR
Number of subjects: 30

Group type: COMPARATOR
Intervention: Truview EVO2 vs Macintosh laryngoscope in CPR scenario
Number of subjects: 30

Group type: COMPARATOR
Intervention: Truview EVO2 vs Macintosh laryngoscope in no-CPR scenario
Number of subjects: 30

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Truview EVO2 laryngoscope
Number of subjects: 30
Study: 22651880

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents (EESs)
Number of subjects: 3687

Group type: COMPARATOR
Intervention: Paclitaxel-eluting stents (PESs)
Number of subjects: 3687
Study: 20386463

Group type: EXPERIMENTAL
Intervention: GOLFIG chemoimmunotherapy (gemcitabine, oxaliplatin, 5‐fluorouracil/folinic acid, granulocyte macrophage colony‐stimulating factor, and aldesleukine)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Treg high score
Number of subjects: 57
Study: 18356602

Group type: EXPERIMENTAL
Intervention: Genital HIV-neutralizing IgA
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: HIV-specific proliferation
Number of subjects: 113

Group type: COMPARATOR
Intervention: HIV-specific IFNgamma production
Number of subjects: 113

Group type: COMPARATOR
Intervention: Genital herpes (HSV2)
Number of subjects: 113
Study: 16051499

Group type: EXPERIMENTAL
Intervention: Threshold therapy with 30% load
Number of subjects: 14
Study: 11518831

Group type: EXPERIMENTAL
Intervention: GH dosage group A, 4 IU/m(2)/d
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: GH dosage group B, first year 4 IU/m(2)/d, thereafter 6 IU/m(2)/d
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: GH dosage group C, first year 4 IU/m(2)/d, second year 6 IU/m(2)/d, thereafter 8 IU/m(2)/d
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (no GH treatment)
Number of subjects: 68
Study: 9625091

Group type: EXPERIMENTAL
Intervention: Olestra (20-35 g)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo triacylglycerol
Number of subjects: 51
Study: 7933659

Group type: EXPERIMENTAL
Intervention: 1800 mg IPA-E
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 900 mg IPA-E
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control (pre-administration values)
Number of subjects: 34
Study: 2463717

Group type: EXPERIMENTAL
Intervention: 400 mg metoprolol per day
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 200 mg metoprolol per day
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 30141180

Group type: EXPERIMENTAL
Intervention: Cinacalcet (0.25 mg/kg)
Number of subjects: 12
Study: 28346377

Group type: EXPERIMENTAL
Intervention: Beamforming transmission (randomized beamforming and center-directed)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of UCA and randomized beamforming scheme
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Number of antenna elements and degree of path loss
Number of subjects: 0

Group type: COMPARATOR
Intervention: Omnidirectional antennas
Number of subjects: 0
Study: 25502081

Group type: EXPERIMENTAL
Intervention: Ulinastatin
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 23515464

Group type: EXPERIMENTAL
Intervention: Proactive recruitment method (referred in person by oncologist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reactive recruitment method (letters mailed through oncologist's office)
Number of subjects: 0
Study: 21465778

Group type: EXPERIMENTAL
Intervention: Structural resonance electromagnetotherapy (SRT)
Number of subjects: 0
Study: 19451573

Group type: EXPERIMENTAL
Intervention: Custom‐made neoprene splint
Number of subjects: 112

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 112
Study: 16423666

Group type: EXPERIMENTAL
Intervention: Myocardial performance index (MPI) of 0.50 or higher
Number of subjects: 512

Group type: COMPARATOR
Intervention: Baseline MPI less than 0.50
Number of subjects: 512
Study: 15567053

Group type: EXPERIMENTAL
Intervention: TFL-assisted treatment group
Number of subjects: 50

Group type: COMPARATOR
Intervention: Traditional treatment group
Number of subjects: 50
Study: 11763512

Group type: EXPERIMENTAL
Intervention: Trisekvens
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Trisekvens plus betaksolol (10‐20 mg/day)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Betaksolol
Number of subjects: 60
Study: 9209440

Group type: EXPERIMENTAL
Intervention: Interferon alpha (IFN)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Hydroxyurea
Number of subjects: 4
Study: 7965451

Group type: EXPERIMENTAL
Intervention: Marine oil source of docosahexaenoic acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard infant formula
Number of subjects: 0
Study: 30850453

Group type: EXPERIMENTAL
Intervention: Five Wishes
Number of subjects: 2748

Group type: COMPARATOR
Intervention: Oklahoma Advance Directive (OKAD)
Number of subjects: 2748
Study: 30477210

Group type: EXPERIMENTAL
Intervention: Intensive oral health instruction at baseline and self-assessment every three months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensive oral health instruction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0
Study: 27345158

Group type: EXPERIMENTAL
Intervention: E2/NETA (1 mg estradiol and 0.5 mg norethisterone acetate)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Tibolone (2.5 mg)
Number of subjects: 50
Study: 25208233

Group type: EXPERIMENTAL
Intervention: Sugammadex 4 mg/kg
Number of subjects: 1184

Group type: COMPARATOR
Intervention: Usual care (neostigmine or spontaneous recovery)
Number of subjects: 1184
Study: 22608582

Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg ketamine
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg ketamine
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg ketamine
Number of subjects: 192
Study: 19995467

Group type: EXPERIMENTAL
Intervention: Indicated Prevention Programme for Externalizing Problem behaviour (PEP)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Control group (nontreated)
Number of subjects: 155
Study: 18160677

Group type: EXPERIMENTAL
Intervention: Interactive interviews
Number of subjects: 1058

Group type: COMPARATOR
Intervention: Face-to-face interviews
Number of subjects: 1058

Group type: COMPARATOR
Intervention: ACASI
Number of subjects: 1058
Study: 16888464

Group type: EXPERIMENTAL
Intervention: Active recovery (approximately 32% VO2max)
Number of subjects: 9
Study: 12794019

Group type: EXPERIMENTAL
Intervention: Lymphoseek (1 nmol; molecular weight, 28 kDa; diameter,.007 micro m)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Filtered [(99m)Tc]sulfur colloid (fTcSC) (.2 micro m)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lymphoseek
Number of subjects: 12

Group type: COMPARATOR
Intervention: fTcSC
Number of subjects: 12
Study: 10801082

Group type: EXPERIMENTAL
Intervention: Isometric contraction at 2% MVC
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Isometric contraction at 5% MVC
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Isometric contraction at 10% MVC
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Isometric contraction at 20% MVC
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Isometric contraction at 30% MVC
Number of subjects: 8

Group type: COMPARATOR
Intervention: Sham trials (no active pull)
Number of subjects: 8
Study: 9251452

Group type: EXPERIMENTAL
Intervention: Sodium Nitroprusside (SNP) added peritoneal dialysis (PD) with 36 cycles of intermittent PD, exchange volume of 1 litre, duration of 1 hour per cycle, SNP dose of 4 mg/litre in alternate clearance periods.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard haemodialysis (HD) for 4 hours.
Number of subjects: 30
Study: 1735861

Group type: EXPERIMENTAL
Intervention: 3.5 mm incision with implantation of an Allergan Medical Optics three‐piece SI‐18NB silicone lens
Number of subjects: 112

Group type: COMPARATOR
Intervention: 6.0 mm incision with implantation of a three‐piece biconvex poly(methyl methacrylate) lens
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 112
Study: 6698337

Group type: COMPARATOR
Intervention: Placebo (5 patients)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Lysine acetylsalicylate (7 patients)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (7 patients)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Aspirin treatment (2 g per day for one week)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Aspirin vs. Lysine acetylsalicylate
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Aspirin treatment
Number of subjects: 19
Study: 31619260

Group type: EXPERIMENTAL
Intervention: short-term prophylaxis strategy
Number of subjects: 0
Study: 29233060

Group type: EXPERIMENTAL
Intervention: Fear appeals intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-threatening intervention
Number of subjects: 0
Study: 27663627

Group type: EXPERIMENTAL
Intervention: Immediate glasses
Number of subjects: 117

Group type: COMPARATOR
Intervention: Observation and glasses if deterioration occurred
Number of subjects: 117
Study: 24193227

Group type: EXPERIMENTAL
Intervention: Dietary intervention
Number of subjects: 61

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 61
Study: 22160514

Group type: EXPERIMENTAL
Intervention: Single-bundle technique
Number of subjects: 84

Group type: COMPARATOR
Intervention: Double-bundle technique
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 84
Study: 19158208

Group type: EXPERIMENTAL
Intervention: Total quantified flavonoid intake (quercetin, kaempferol, myricetin, apigenin, luteolin)
Number of subjects: 38408

Group type: EXPERIMENTAL
Intervention: Flavonoid-rich foods (tea, apple, broccoli, onion, tofu)
Number of subjects: 38408
Study: 17846548

Group type: EXPERIMENTAL
Intervention: Sinus augmentation with 100% autologous bone
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Sinus augmentation with 100% Bio‐Oss
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (preexisting subantral bone)
Number of subjects: 24
Study: 14963469

Group type: EXPERIMENTAL
Intervention: Neurogenic ED group (n=23)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Vasculogenic ED group (n=23)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (n=12)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Vasculogenic ED with arterial risk factors
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Patients achieving full erection at pharmacological test
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Correlation with bioavailable testosterone levels
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Correlation with DHEA-S levels
Number of subjects: 46
Study: 11779741

Group type: EXPERIMENTAL
Intervention: Oral jaw-positioning appliance (6-month trial)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 32
Study: 9678813

Group type: EXPERIMENTAL
Intervention: RBC 400 mg b.d. plus clarithromycin 250 mg t.d.s. and tinidazole 500 mg b.d. (group RBCCT)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: RBC 400 mg b.d. plus clarithromycin 250 mg t.d.s. plus amoxycillin 1 g b.d. (group RBCCA)
Number of subjects: 70
Study: 7862890

Group type: EXPERIMENTAL
Intervention: Nicotine injections (0.6 mg, subcutaneous, two injections 40 min apart)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 2777568

Group type: EXPERIMENTAL
Intervention: BLS-course A (hospital-wide Heartsaver course)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: BLS-course C (Basic Cardiac Life Support course)
Number of subjects: 90
Study: 1239491

Group type: EXPERIMENTAL
Intervention: Experimental group (frustration with difficult puzzle)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (easier task)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Experimental group (frustration)
Number of subjects: 44
Study: 31533016

Group type: EXPERIMENTAL
Intervention: Pursuit condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fixation condition
Number of subjects: 0
Study: 28540893

Group type: EXPERIMENTAL
Intervention: Acetate-free biofiltration with profiled potassium (AFBK)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Online hemodiafiltration (olHDF)
Number of subjects: 10
Study: 25988589

Group type: EXPERIMENTAL
Intervention: Brief alcohol intervention delivered by community pharmacists (n=205)
Number of subjects: 407

Group type: COMPARATOR
Intervention: Leaflet-only control condition (n=202)
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Brief alcohol intervention (n=205)
Number of subjects: 407